Avalo Therapeutics Inc
NASDAQ:AVTX
Intrinsic Value
Avalo Therapeutics, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one AVTX stock under the Base Case scenario is 38.81 USD. Compared to the current market price of 14.2 USD, Avalo Therapeutics Inc is Undervalued by 63%.
Valuation Backtest
Avalo Therapeutics Inc
Run backtest to discover the historical profit from buying and selling AVTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Avalo Therapeutics Inc
Current Assets | 8.4m |
Cash & Short-Term Investments | 7.4m |
Receivables | 136k |
Other Current Assets | 844k |
Non-Current Assets | 12.6m |
PP&E | 2m |
Intangibles | 10.5m |
Other Non-Current Assets | 131k |
Current Liabilities | 4.6m |
Accounts Payable | 446k |
Accrued Liabilities | 4.2m |
Non-Current Liabilities | 9.1m |
Other Non-Current Liabilities | 9.1m |
Earnings Waterfall
Avalo Therapeutics Inc
Revenue
|
1.9m
USD
|
Cost of Revenue
|
-1.3m
USD
|
Gross Profit
|
640k
USD
|
Operating Expenses
|
-24.1m
USD
|
Operating Income
|
-23.4m
USD
|
Other Expenses
|
-8.1m
USD
|
Net Income
|
-31.5m
USD
|
Free Cash Flow Analysis
Avalo Therapeutics Inc
AVTX Profitability Score
Profitability Due Diligence
Avalo Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Avalo Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
AVTX Solvency Score
Solvency Due Diligence
Avalo Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Avalo Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVTX Price Targets Summary
Avalo Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AVTX is 35.7 USD with a low forecast of 35.35 USD and a high forecast of 36.75 USD.
Ownership
AVTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AVTX Price
Avalo Therapeutics Inc
Average Annual Return | -41.52% |
Standard Deviation of Annual Returns | 28.13% |
Max Drawdown | -100% |
Market Capitalization | 11.4m USD |
Shares Outstanding | 801 611 |
Percentage of Shares Shorted | 7.59% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Avalo Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 42 full-time employees. The company went IPO on 2015-11-13. The firm discovers, develops, and commercializes therapeutics for patients with unmet clinical needs in immunology and rare genetic diseases. Its clinical-stage pipeline includes AVTX-002, AVTX-007, and AVTX-800 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, moderate to severe inflammatory bowel disease, and COVID-19 acute respiratory distress syndromes. AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA). Its AVTX-800 programs include AVTX-801 and AVTX-803, AVTX-802, AVTX-008, and AVTX-006. VTX-801 and AVTX-803 are monosaccharide therapies for the treatment of congenital disorders of glycosylation (CDGs). AVTX-006 is a dual mTORc1/c2 small molecule inhibitor for the treatment of complex lymphatic malformations.
Contact
IPO
Employees
Officers
The intrinsic value of one AVTX stock under the Base Case scenario is 38.81 USD.
Compared to the current market price of 14.2 USD, Avalo Therapeutics Inc is Undervalued by 63%.